Table 5.
Summary of co-delivery of small molecule drug and siRNA by dendrimer-based nanomaterials for cancer therapy.
| Delivery System | Small Molecule Drug | siRNA Target |
Type of Cancer | Cell Line | Testing Stage | Ref. |
|---|---|---|---|---|---|---|
| Amphiphilic dendrimer engineered nanocarrier system (ADENS) modified by tumour microenvironment-sensitive polypeptides (TMSP) (TMSP-ADENS) | Paclitaxel | FAM and VEGF group | Melanoma, prostate cancer |
A375, PC-3, HT-1080 |
In vitro
In vivo |
[13] |
| PTP (plectin-1 targeted peptide, NH2-KTLLPTP-COOH), biomarker for pancreatic cancer, integrated with the PSPG vector to form peptide-conjugated PSPG (PSPGP) where PSPG is branched poly(ethylene glycol) with G2 dendrimers through disulfide linkages |
Paclitaxel | NR4A1 (or TR3) | Pancreatic Cancer | Panc-1 |
In vitro
In vivo |
[83] |
| Hyaluronic acid (HA) modified MDMs where MDMs is the PAMAM-PEG2k-DOPE co-polymer, together with mPEG2k-DOPE, was formulated into mixed dendrimer micelles, and PAMAM is the generation 4 polyamidoamine |
Doxorubicin | ABCB1 (or MDR1) | Ovarian cancer, colorectal carcinoma and breast cancer | A2780 ADR, HCT 116, MDA-MB-231 |
In vitro | [86] |
| PAMAM-OH derivative (PAMSPF) | Murine double minute 2 protein (MDM2) inhibitor RG7388 | TP53 | Breast cancer | P53-wild type MCF-7 cells (MCF-7/WT), MDA-MB-435 |
In vitro
In vivo |
[87] |
| Polyamidoamine (PAMAM) dendrimer | Curcumin | BCL2 | Cervical cancer | HeLa | In vitro | [91] |
| Folate-polyethylene glycol appended dendrimer conjugate with glucuronylglucosyl-β cyclodextrin (Fol-PEG-GUG-β-CDE) (generation 3) | Doxorubicin | PLK1 | Cervical cancer | KB |
In vitro
In vivo |
[92] |
Note: BCL2, BCL2 apoptosis regulator; NR4A1, nuclear receptor subfamily 4 group A member 1; TR3, thioredoxin reductase 3; ABCB1, ATP binding cassette subfamily B member 1; MDR1, multidrug resistance protein 1; FAM, long non-coding family with sequence group; VEGF, vascular endothelial growth factor group; TP53, tumour protein p53.